A new report by an international team of experts is calling for a "grand bargain" to improve the antibiotic development market.

The report, released last week by the Center for Global Development, calls for governments and drug makers to negotiate and come to a political understanding that would help fix the antibiotic development market. Such an agreement is needed because the current market, the report argues, is failing to spur antibiotic research and development (R&D), ensure equitable access to new antibiotics, and protect antibiotics from overuse.

"These three problems all need to be fixed to build a market that is fit for purpose," the authors of the report wrote in a blog post.

The aim of the proposed political agreement would be to ensure that countries—particularly high-income countries—provide adequate funding for antibiotic R&D, protect antibiotics from inappropriate use, and ensure that essential antibiotics are accessible to all who need them. The pharmaceutical industry, in turn, would have to commit to conducting research on new antibiotics and ensuring equitable access. International organizations like the United Nations (UN) and the World Health Organization would play a role in implementing and coordinating the system.

Collective action needed

The authors say that while some countries and stakeholders have taken steps to address the failure of the antibiotic market, collective international action is needed to combat rising antimicrobial resistance (AMR).

"Tackling AMR requires global consensus and action on many fronts," they wrote. "Creating an antimicrobial market that ensures adequate innovation, access, and stewardship is key to fighting AMR."

To create this market, the report recommends establishing one or several hubs that would facilitate sustainable access to essential antibiotics in low- and middle-income countries; implementing policies to ensure that antibiotic innovation is properly valued; strengthening regional approaches to regulating and approving antibiotics; enacting systems to track, control, and measure antibiotic use; and setting targets to track progress on innovation, access, and stewardship goals.

The authors say they hope that an agreement can be reached by the next UN General Assembly in September 2024, when member states will hold a high-level meeting on AMR.

Creating an antimicrobial market that ensures adequate innovation, access, and stewardship is key to fighting AMR.

Three Pfizer/BioNTech COVID-19 vaccine doses stimulate long-term immune responses against SARS-CoV-2 similar to breakthrough infection plus two doses, while four doses only temporarily increase antibody levels, according to a new study in the International Journal of Infectious Diseases.

Every 2 to 4 months, researchers at Ziv Medical Center in Israel measured anti-spike SARS-CoV-2 immunoglobulin G (IgG) levels in healthcare workers (HCWs) who received at least two Pfizer COVID-19 doses and either had more doses and/or were infected up to 22 months after the second dose.

The study, which ended in September 2022, was a follow-up to one published in Clinical Infectious Diseases in March 2022.

Fourth dose may be best suited for high-risk groups

Most workers (62%) had received three COVID-19 vaccine doses, while 16% received two, 14% had four, and 8% had one, of whom 70 were vaccinated after infection.

Among 993 HCWs, infection after dose two led to higher IgG geometric mean titers (GMCs) than receipt of a third dose (4,285 vs 2,845 arbitrary units per milliliter [mL] 1 or 2 months after infection or vaccination).

The role of the fourth dose is different and may be more suited to providing additional short-term protection to individuals at high risk of severe outcomes, or during times of increased risk of exposure, such as periods of intense transmission.

Sixteen to 18 months after dose two, HCWs who were infected or received three or four vaccine doses had IgG GMCs higher than 500 arbitrary unit/ml, with no significant between-group differences. IgG levels leveled off 16 to 22 months after the second dose.

IgG levels surpassed the correlate of protection against the wild-type and Delta strains, but it's unclear clear how they stack up to those required against Omicron strains, which are probably much higher considering the lower effectiveness of the original Pfizer vaccine against Omicron, the researchers said.

Four to 6 months after a fourth dose, IgG levels had regressed to three-dose levels.

"The role of the fourth dose is different and may be more suited to providing additional short-term protection to individuals at high risk of severe outcomes, or during times of increased risk of exposure, such as periods of intense transmission," the study authors wrote.

The Centers for Disease Control and Prevention (CDC) last week announced $262 million in funding over next 5 years to 13 recipients to establish its first national network for detecting and responding more efficiently to public health emergencies.

Called the National Network for Outbreak Response and Disease Modeling, the program reflects representation from state health departments, tribal organizations, and the private sector. Eleven of the 13 recipients are universities, including, for example, the University of Minnesota, Johns Hopkins University, and Emory University.

The institutions will work as a network to conduct landscape analysis to identify gaps, needs, and opportunities for outbreak analytics and disease modeling. They will also pilot and implement analytic technologies and prepare for and response to infectious disease threats.

Dylan George, PhD, who directs the CDC's Center for Forecasting and Outbreak Analytics, said collaboration over the last year has been crucial for delivering decision support to leaders and improving outbreak response. "Building upon that experience by establishing this national network will help us better respond to outbreaks and prevent pandemics in the future," he said.